User profiles for Eran Kotler

Eran Kotler

Stanford University
Verified email at stanford.edu
Cited by 2913

[PDF][PDF] Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features

…, U Mor, M Dori-Bachash, S Bashiardes, E Kotler… - Cell, 2018 - cell.com
Empiric probiotics are commonly consumed by healthy individuals as means of life quality
improvement and disease prevention. However, evidence of probiotic gut mucosal …

[PDF][PDF] Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT

…, Y Cohen, AE Moor, D Zeevi, T Korem, E Kotler… - Cell, 2018 - cell.com
Probiotics are widely prescribed for prevention of antibiotics-associated dysbiosis and
related adverse effects. However, probiotic impact on post-antibiotic reconstitution of the gut …

[PDF][PDF] A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation

E Kotler, O Shani, G Goldfeld, M Lotan-Pompan… - Molecular cell, 2018 - cell.com
The TP53 gene is frequently mutated in human cancer. Research has focused predominantly
on six major "hotspot" codons, which account for only ∼30% of cancer-associated p53 …

[PDF][PDF] RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation

G Fuchs, E Shema, R Vesterman, E Kotler… - Molecular cell, 2012 - cell.com
Embryonic stem cells (ESCs) maintain high genomic plasticity, which is essential for their
capacity to enter diverse differentiation pathways. Posttranscriptional modifications of …

[HTML][HTML] Deterministic evolution and stringent selection during preneoplasia

K Karlsson, MJ Przybilla, E Kotler, A Khan, H Xu… - Nature, 2023 - nature.com
The earliest events during human tumour initiation, although poorly characterized, may hold
clues to malignancy detection and prevention 1 . Here we model occult preneoplasia by …

[HTML][HTML] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US …

…, A Mani, HW Chen, J Dering, B Adams, E Kotler… - Nature …, 2020 - nature.com
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …

Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival

…, I Oršolić, T Shalit, O Tarcic, E Kotler… - Proceedings of the …, 2017 - National Acad Sciences
The microRNA miR-504 targets TP53 mRNA encoding the p53 tumor suppressor. miR-504
resides within the fibroblast growth factor 13 (FGF13) gene, which is overexpressed in …

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

KL McNamara, JL Caswell-Jin, R Joshi, Z Ma, E Kotler… - Nature cancer, 2021 - nature.com
The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved
pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer…

N‐Methylation of isopeptide bond as a strategy to resist deubiquitinases

…, N Eltarteer, S Ohayon, E Shema, E Kotler… - Angewandte …, 2012 - infona.pl
Hoher Widerstand: Mithilfe einer effizienten Methode zum Aufbau N‐methylierter
Isopeptidbindungen wurden stabile ubiquitinierte Peptide und Proteine hergestellt, die …

Experimental evolution in TP53 deficient human gastric organoids recapitulates tumorigenesis

K Karlsson, M Przybilla, H Xu, E Kotler, K Karagyozova… - BioRxiv, 2022 - biorxiv.org
The earliest events during human tumor initiation, while poorly characterized, may hold
clues to malignancy detection and prevention 1 . Here we model occult pre-neoplasia by bi-…